Optimi Health Corp. (CSE: OPTI | Nasdaq: OPTH | FSE: 8BN), a commercial-stage pharmaceutical manufacturer focused on regulated psychedelic drug products, has announced it will participate in the ThinkEquity Conference on October 15, 2026, in New York City. Management will deliver a corporate overview and hold one-on-one meetings with registered investors. The appearance gives Optimi an opportunity to raise its profile among U.S. institutional and retail investors as it advances its psychedelic medicine pipeline.

Key Points

  • Optimi Health Corp. (CSE: OPTI | Nasdaq: OPTH)
  • Management will present a corporate overview at the ThinkEquity Conference on October 15, 2026, at the Mandarin Oriental Hotel in New York City at 4:00 p.m. Eastern time
  • One-on-one investor meetings will be available to registered conference attendees through their ThinkEquity representative
  • Investors may watch for management commentary on Optimi's GMP-grade psychedelic product supply and international clinical program access

Optimi's Presence at ThinkEquity's New York Event

Optimi Health confirmed it will take part in the ThinkEquity Conference at the Mandarin Oriental Hotel in New York City on October 15, 2026. Management is scheduled to present a corporate overview at 4:00 p.m. Eastern time. In addition to the formal presentation, company representatives will be available for one-on-one meetings with investors who are registered for the event. Investors wishing to schedule a meeting were directed to contact their ThinkEquity representative or register through the conference portal referenced in the announcement.

Optimi's GMP Manufacturing and Regulated Product Portfolio

Optimi operates as a Health Canada-licensed pharmaceutical manufacturer producing GMP-grade MDMA and botanical psilocybin drug products at its British Columbia facilities. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. The release states that Optimi's products are currently prescribed to patients in Australia under that country's Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program, positioning the company within a small group of licensed psychedelic drug manufacturers globally.

Investor Access and Conference Strategy for Psychedelic Pharma

Conference participation is a common investor-relations strategy for emerging pharmaceutical companies seeking to broaden awareness among institutional audiences. By presenting at a recognised equity-focused event, Optimi signals continued engagement with the North American investment community. The company holds listings on three exchanges — the CSE, Nasdaq, and Frankfurt Stock Exchange — reflecting its cross-border investor base. The immediate share price impact was not clear from available public information.